Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2007 1
2008 1
2009 1
2012 1
2015 3
2016 3
2017 3
2018 3
2019 4
2020 10
2021 8
2022 13
2023 21
2024 23
2025 26
2026 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for anh tuan le
Search for Nam Tuan Le instead (2 results)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8. N Engl J Med. 2017. PMID: 28885881 Free article. Clinical Trial.
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Reyes Contreras J, Reck M, Palmero R, Mak MP, Hu Y, Morris S, Höglander E, Connors M, Biggane AM, Vollan HK, Peters S. Lee SM, et al. Among authors: le at. Lancet. 2023 Aug 5;402(10400):451-463. doi: 10.1016/S0140-6736(23)00774-2. Epub 2023 Jul 6. Lancet. 2023. PMID: 37423228 Clinical Trial.
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, Hayashi H, Nhung NV, Chia PL, de Marinis F, Raskin J, Zhou Q, Finocchiaro G, Le AT, Wang J, Dooms C, Kato T, Nadal E, Hin HS, Smit EF, Wermke M, Tan D, Morise M, O'Brate A, Adrian S, Pfeiffer BM, Stroh C, Juraeva D, Strotmann R, Goteti K, Berghoff K, Ellers-Lenz B, Karachaliou N, Le X, Kim TM; INSIGHT 2 investigators. Wu YL, et al. Among authors: le at. Lancet Oncol. 2024 Aug;25(8):989-1002. doi: 10.1016/S1470-2045(24)00270-5. Lancet Oncol. 2024. PMID: 39089305 Clinical Trial.
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J, Kim TW; CONCUR Investigators. Li J, et al. Among authors: le at. Lancet Oncol. 2015 Jun;16(6):619-29. doi: 10.1016/S1470-2045(15)70156-7. Epub 2015 May 13. Lancet Oncol. 2015. PMID: 25981818 Clinical Trial.
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.
Peters S, Schulz C, Reck M, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Contreras JR, Palmero R, Mak MP, Popat S, Hu Y, Morris S, Srivastava MK, Kaul M, Graupner V, Gitlitz B, Lee SM. Peters S, et al. Among authors: le at. J Thorac Oncol. 2025 Dec;20(12):1843-1850. doi: 10.1016/j.jtho.2025.07.115. Epub 2025 Jul 22. J Thorac Oncol. 2025. PMID: 40706710 Clinical Trial.
Antibacterial activity of a berberine nanoformulation.
Nguyen HT, Pham TN, Le AT, Thuy NT, Huy TQ, Nguyen TTT. Nguyen HT, et al. Among authors: le at. Beilstein J Nanotechnol. 2022 Jul 11;13:641-652. doi: 10.3762/bjnano.13.56. eCollection 2022. Beilstein J Nanotechnol. 2022. PMID: 35923171 Free PMC article.
A 2D semiconductor-self-assembled monolayer photoswitchable diode.
Margapoti E, Li J, Ceylan Ö, Seifert M, Nisic F, Anh TL, Meggendorfer F, Dragonetti C, Palma CA, Barth JV, Finley JJ. Margapoti E, et al. Among authors: anh tl. Adv Mater. 2015 Feb 25;27(8):1426-31. doi: 10.1002/adma.201405110. Epub 2015 Jan 12. Adv Mater. 2015. PMID: 25641369
First-line atezolizumab monotherapy vs . single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation.
Han B, Peters S, Le AT, Huang D, Wu G, Cao L, Pham CP, Zhao J, Wang K, Yang N, Zhong H, Hu Y, Morris S, Lam V, Graupner V, Gitlitz B, Hoglander E, Schulz C, Lee SM. Han B, et al. Among authors: le at. Chin Med J (Engl). 2026 Jun 20;139(12):1838-1845. doi: 10.1097/CM9.0000000000003796. Epub 2025 Dec 17. Chin Med J (Engl). 2026. PMID: 41424028 Free PMC article. Clinical Trial.
127 results